Watertown, MA – According to filings with the U.S. Securities and Exchange Commission, Tarveda Therapeutics is raising $15,433,472.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Brian Roberts played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Tarveda Therapeutics

Tarveda’s mission is to discover, develop and commercialize a new class of potent and selective precision oncology medicines for the treatment of patients with various solid tumor malignancies. Tarveda develops its Pentarin miniature drug conjugates to enhance the effectiveness of promising anti-cancer payloads by selectively targeting them to solid tumors. Our precision oncology medicines are designed to rapidly penetrate solid tumors, selectively bind to the desired tumor targets, and accumulate their anti-cancer payloads.

To learn more about Tarveda Therapeutics, visit http://www.tarveda.com/

Contact:
Brian Roberts, President and Chief Executive Officer
617-923-4100
https://www.linkedin.com/in/brian-roberts-77189a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved